Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy

Iihara,Hirotoshi; Hirose,Chiemi; Funaguchi,Norihiko; Endo,Junki; Ito,Fumitaka; Yanase,Komei; Kaito,Daizo; Ohno,Yasushi; Suzuki,Akio

doi:10.3892/mco.2021.2278

Evaluation of clinical pharmacist interventions for adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy

Authors:
- Hirotoshi Iihara
- Chiemi Hirose
- Norihiko Funaguchi
- Junki Endo
- Fumitaka Ito
- Komei Yanase
- Daizo Kaito
- Yasushi Ohno
- Akio Suzuki
View Affiliations

Affiliations: Department of Pharmacy, Gifu University Hospital, Gifu 501‑1194, Japan, Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan
Published online on: April 8, 2021 https://doi.org/10.3892/mco.2021.2278
Article Number: 116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the increasing complexity of cancer chemotherapy and its associated supportive care, the role of clinical pharmacists in cancer chemotherapy is becoming increasingly more important. The present study evaluated the clinical interventions of a single pharmacist on the adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy. A single‑center, retrospective study was conducted at the 614‑bed, tertiary care Gifu University Hospital. Hospitalized patients with thoracic cancer who received cancer chemotherapy in the respiratory medicine ward between April 2013 and May 2014 were enrolled. One of the two clinical pharmacists in charge was based in the respiratory medicine ward and implemented pharmaceutical care for the patients, including management of adverse events. Patient data were recorded in the electronic medical chart and retrospectively analyzed. A total of 445 patients with thoracic cancer received cancer chemotherapy in the respiratory medicine ward. A total of 152 interventions (101 patients) were performed by the clinical pharmacist prior to the administration of cancer chemotherapy, half of which comprised the addition of drugs to prevent adverse events. A total of 190 patients (39.4%) experienced grade ≥2 non‑hematological or grade ≥3 hematological adverse events associated with cancer chemotherapy, and 223 medical interventions for relief of adverse events lowered the incidence of grade ≥2 non‑hematological or grade ≥3 hematological adverse events to 17.8%. Of these, 45.3 and 7.5% of medical interventions for non‑hematological and hematological adverse events, respectively, were implemented based on the pharmacist's recommendations. These findings revealed the marked contribution of a single clinical pharmacist in the respiratory medicine ward to the prevention and relief of adverse events in hospitalized patients with thoracic cancer receiving cancer chemotherapy.

View Figures

View References

1	Vincent C, Neale G and Woloshynowych M: Adverse events in British hospitals: Preliminary retrospective record review. BMJ. 322:517–519. 2001.PubMed/NCBI View Article : Google Scholar
2	Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J, Etchells E, Ghali WA, Hébert P, Majumdar SR, et al: The Canadian adverse events study: The incidence of adverse events among hospital patients in Canada. CMAJ. 170:1678–1686. 2004.PubMed/NCBI View Article : Google Scholar
3	Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ and Lalla D: Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real world setting. Oncologist. 19:901–908. 2014.PubMed/NCBI View Article : Google Scholar
4	Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P and Guerin A: Assessment of costs associated with adverse events in patients with cancer. PLoS One. 13(e0196007)2018.PubMed/NCBI View Article : Google Scholar
5	Rashid N, Koh HA, Baca HC, Li Z, Malecha S, Abidoye O and Masaquel A: Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm. 21:863–871. 2015.PubMed/NCBI View Article : Google Scholar
6	Caggiano V, Weiss RV, Rickert TS and Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 103:1916–1924. 2005.PubMed/NCBI View Article : Google Scholar
7	Shune SE, Karnell LH, Karnell MP, Van Daele DJ and Funk GF: Association between severity of dysphagia and survival in patients with head and neck cancer. Head Neck. 34:776–784. 2012.PubMed/NCBI View Article : Google Scholar
8	Mathijssen RH, Sparreboom A and Verweij J: Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 11:272–281. 2014.PubMed/NCBI View Article : Google Scholar
9	Ranchon F, Salles G, Späth HM, Schwiertz V, Vantard N, Parat S, Broussais F, You B, Tartas S, Souquet PJ, et al: Chemotherapeutic errors in hospitalised cancer patients: Attributable damage and extra costs. BMC Cancer. 11(478)2011.PubMed/NCBI View Article : Google Scholar
10	Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY and Pamer C: Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm. 58:1835–1841. 2001.PubMed/NCBI View Article : Google Scholar
11	Chewning B and Wiederholt JB: Concordance in cancer medication management. Patient Educ Couns. 50:75–78. 2003.PubMed/NCBI View Article : Google Scholar
12	Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL and Bruera E: Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: A retrospective descriptive study. J Pain Symptom Manage. 27:481–491. 2004.PubMed/NCBI View Article : Google Scholar
13	Iihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y, Yoshida K and Itoh Y: Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract. 18:753–760. 2012.PubMed/NCBI View Article : Google Scholar
14	Shah S, Dowell J and Greene S: Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother. 40:1527–1533. 2006.PubMed/NCBI View Article : Google Scholar
15	Han JM, Ah YM, Suh SY, Jung SH, Hahn HJ, Im SA and Lee JY: Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit. Int J Clin Pharm. 38:1124–1132. 2016.PubMed/NCBI View Article : Google Scholar
16	Shah S, Dowell J and Greene S: Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother. 40:1527–1533. 2016.PubMed/NCBI View Article : Google Scholar
17	Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K, Igarashi T and Yamaguchi M: Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J Oncol Pharm Pract. 25:1558–1563. 2018.PubMed/NCBI View Article : Google Scholar
18	Martin JK Jr and Norwood MB: Pharmacist management of antiemetic therapy under protocol in an oncology clinic. Am J Hosp Pharm. 45:1322–1328. 1988.PubMed/NCBI
19	Horne AL and Dapolite LA: Protocol for pharmacist management of antineoplastic drug-induced adverse effects in outpatients. Am J Health Syst Pharm. 54:680–683. 1997.PubMed/NCBI View Article : Google Scholar
20	Gums TH, Uribe L, Vander Weg MW, James P, Coffey C and Carter BL: Pharmacist intervention for blood pressure control: Medication intensification and adherence. J Am Soc Hypertens. 9:569–578. 2015.PubMed/NCBI View Article : Google Scholar
21	Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M and Ionescu-Ittu R: Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer. 119:112–119. 2018.PubMed/NCBI View Article : Google Scholar
22	Rashid N, Koh HA, Baca HC, Lin KJ, Malecha SE and Masaquel A: Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer. 8:173–181. 2016.PubMed/NCBI View Article : Google Scholar
23	Suzuki A, Kobayashi R, Okayasu S, Kuze B, Aoki M, Mizuta K and Itoh Y: Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: A single arm intervention study. PLoS One. 9(e115879)2014.PubMed/NCBI View Article : Google Scholar
24	Hou S, Huh B, Kim HK, Kim KH and Abdi S: Treatment of chemotherapy-induced peripheral neuropathy: Systematic review and recommendations. Pain Physician. 21:571–592. 2018.PubMed/NCBI
25	Classen DC, Pestotnik SL, Evans RS, Lloyd JF and Burke JP: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 277:301–306. 1997.PubMed/NCBI
26	Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ and Leape LL: The costs of adverse drug events in hospitalized patients. JAMA. 277:307–311. 1997.PubMed/NCBI
27	Nishida S, Hayashi Y, Suzuki A, Kobayashi R, Inuzuka T and Itoh Y: Relationship between number of drugs and duration of hospital stay in older patients with neuromuscular diseases. Geriatr Gerontol Int. 18:1018–1024. 2018.PubMed/NCBI View Article : Google Scholar